Tymara Berry

机构：Geron (United States), Gilead Sciences (United States)

发表论文 63 篇 · 总被引 685 次 · h-index 10

代表论文

• Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science (2024 · Clinical and Translational Science · 被引 31)
• Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial (2024 · Blood · 被引 6)
• Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor (2024 · CPT Pharmacometrics & Systems Pharmacology · 被引 6)
• Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF) (2024 · Blood · 被引 5)
• Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis (2025 · Clinical and Translational Science · 被引 3)
• Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis (2025 · Blood · 被引 2)